-
Featured
Maximizing Clinical Utility of Pulmonary Optical Imaging
Massachusetts General Hospital researchers push the limits of pulmonary optical frequency domain imaging for in vivo diagnosis of lung cancer and assessment of asthmatic airways.
-
First-in-Human Trial: Implanted Microdevice for Testing Patient Sensitivity to Multiple Chemotherapeutic Agents in NSCLC
In a first-in-human trial conducted by Yolonda L. Colson, MD, PhD, and colleagues, a multidrug-eluting microdevice implanted intraoperatively into non-small cell lung tumors proved safe and feasible for in situ chemotherapeutic sensitivity testing and was reliably removable by pathologists.
-
Automated Deep Learning Accurately Assesses Muscle and Fat Tissue on Routine Chest CT
Massachusetts General Hospital researchers created a fully automated deep learning system to quantify and characterize muscle and adipose tissue on CT scans at multiple thoracic vertebral levels. The system is as accurate as human analysts on routine CT scans, regardless of intravenous contrast.
-
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
Researchers at the Massachusetts General Hospital Cancer Center and colleagues have identified mutations that make lung cancer resistant to adagrasib and other KRAS-G12C inhibitors. Their findings provide clues to designing next-generation inhibitors and combination regimens.
-
Capmatinib Benefits Adults with Advanced NSCLC and MET Exon 14 Skipping Mutation
Rebecca S. Heist, MD, MPH, and colleagues led the phase 2 GEOMETRY mono-1 trial, the basis for FDA approval of capmatinib, a highly specific new MET inhibitor for treatment of adults with MET exon 14–mutated metastatic non–small-cell lung cancer.
-
Some Physicians Knowingly Order Guideline-Discordant Lung Cancer Screening
Massachusetts General Hospital researchers found that for a small fraction of patients, lung cancer screening examinations were ordered knowingly outside of U.S. guidelines, including for never smokers, motivated in part by cancer risk perceptions.
Lung Cancer Contributors
-
Aaron Hata, MD, PhD
Assistant Physician, Hematology and Oncology, Massachusetts General Hospital, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
-
Aaron L. Baggish, MD
Director, Cardiovascular Performance Program, Director, Cardiovascular Performance Program Fellowship
Recent Article
How COVID-19 Affects the Heart, Especially in Athletes
-
Gary X. Wang, MD, PhD
Diagnostic Radiologist, Department of Radiology, Massachusetts General Hospital
Recent Article
Some Physicians Knowingly Order Guideline-Discordant Lung Cancer Screening -
Melissa J. Suter, PhD
Associate Professor in Medicine, Harvard Medical School, Assistant in Biomedical Engineering, Massachusetts General Hospital
Recent Article
Maximizing Clinical Utility of Pulmonary Optical Imaging -
Michael T. Lu, MD, MPH
Director of Research, Cardiovascular Imaging Division, Co-Director, Cardiovascular Imaging Research Center, Massachusetts General Hospital, Assistant Professor of Radiology, Harvard Medical School
Recent Article
Artificial Intelligence Estimates Biological Age, Predicts Mortality From a Chest X-ray -
Rebecca Suk Heist, MD, MPH
Associate Professor of Medicine at Harvard Medical School, Physician in the Division of Hematology/Oncology, Mass General Cancer Center
Recent Article
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
-
Udo Hoffmann, MD
Director, Cardiac MR PET CT Program, Mass General, Division Chief, Cardiovascular Imaging, Mass General, Professor of Radiology, HMS
Recent Article
Discordance Across High-Sensitivity Troponin Assays Can Affect Management of Suspected ACS
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
